Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 25:9:766871.
doi: 10.3389/fpubh.2021.766871. eCollection 2021.

Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections

Affiliations
Review

Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections

Dhanasekaran Sakthivel et al. Front Public Health. .

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a recently emerged and highly contagious virus that causes coronavirus disease 2019 (COVID-19). As of August 24, 2021, there were more than 212 million confirmed COVID-19 cases and nearly 4.4 million deaths reported globally. Early diagnosis and isolation of infected individuals remains one of the most effective public health interventions to control SARS-CoV-2 spread and for effective clinical management of COVID-19 cases. Currently, SARS-CoV-2 infection is diagnosed presumptively based on clinical symptoms and confirmed by detecting the viral RNA in respiratory samples using reverse transcription polymerase chain reaction (RT-PCR). Standard RT-PCR protocols are time consuming, expensive, and technically demanding, which makes them a poor choice for large scale and point-of-care screening in resource-poor settings. Recently developed isothermal nucleic acid amplification tests (iNAAT), antigen and/or serological tests are cost-effective to scale COVID-19 testing at the point-of-care (PoC) and for surveillance activities. This review discusses the development of rapid PoC molecular tools for the detection and surveillance of SARS-CoV-2 infections.

Keywords: COVID-19; SARS-CoV-2; diagnostics; isothermal amplification (LAMP); point-of-care; sample types; surveillance.

PubMed Disclaimer

Conflict of interest statement

ZiP Diagnostics is commercializing a COVID-19 point of care test. CN, DS, DD-D, WH, and JR have employment at ZiP. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
COVID-19 diagnostic testing through isothermal NAAT. Reverse transcriptase LAMP (RT-LAMP) detection of SARS-CoV-2 RNA in nasal swab and saliva samples. These samples can be stored in the refrigerator for 3 days prior to NAAT testing. Where testing can be done immediately, sample preparation and/or RNA extraction is performed, which may take between 5 and 20 min. RNA purification is often required for RT-PCR-based testing. This is done because contaminants in crude cell lysates could potentially reduce the polymerase activity of the reverse transcriptase and DNA polymerases used in RT-PCR. In contrast, the Bacillus stearothermophilus (Bst) DNA polymerase used in LAMP is more tolerant to inhibitors. For RT-LAMP testing, a set of four to six primers targeting any of the viral genes can be designed using online programs, e.g., Eiken Primer design software. It is recommended that a primer set targeting a human endogenous gene is included as a control for sample preparation/RNA extraction and amplification efficiency. In RT-LAMP, both cDNA synthesis (reverse transcriptase) and amplification (Bst) occur simultaneously and in the same reaction tube at a constant temperature (60–65°C). A double-stranded DNA intercalating dye can be added to detect amplicons either by colorimetry (show color change), fluorescent (for real-time detection) or both. RT-LAMP is prone to false-positive amplifications and as such any assay developed using this technique needs to be standardized for each test type. *In a NAAT-based assay, two targets on N gene were included in a single reaction to increase the test sensitivity. Created with Biorender.com.

Similar articles

Cited by

References

    1. Benitez MA, Velasco C, Sequeira AR, Henriquez J, Menezes FM, Paolucci F. Responses to COVID-19 in five Latin American countries. Health Policy and Technology. (2020) 9:525–59. 10.1016/j.hlpt.2020.08.014 - DOI - PMC - PubMed
    1. WHO . Diagnostic Testing for SARS-CoV-2: Interim Guidance. Available online at: https://apps.who.int/iris/bitstream/handle/10665/334254/WHO-2019-nCoV-la... (accessed April 20, 2021).
    1. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. . Virological assessment of hospitalized patients with COVID-2019. Nature. (2020) 581:465–9. 10.1038/s41586-020-2196-x - DOI - PubMed
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. . Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. (2020) 71:2027–34. 10.1093/cid/ciaa344 - DOI - PMC - PubMed
    1. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. . Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv [preprint]. (2020).

Publication types